Drugs / SC-CAR4BRAIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05768880 | May 2023 → Jan 2028 expected | diffuse intrinsic pontine glioma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-CAR4BRAIN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768880 ↗ |
| Modality | Cell therapy | “autologous CD4+ and CD8+ T cells lentivirally transduced to express to express combinations of B7-H3, EGFR806, HER2, and IL13-zetakine chimeric antigen receptors (CAR)” NCT05768880 ↗ |
| Route | Other | “intraventricular CNS administered SC-CAR4BRAIN infusions” NCT05768880 ↗ |